ArticleTechnology in cancer research & treatment
Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Xuesong Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.